
-
Taysha Gene Therapies NasdaqGS:TSHA Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Location: 3000 Pegasus Park Drive, Dallas, TX, 75247, United States | Website: https://www.tayshagtx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
535.4M
Cash
116.6M
Avg Qtr Burn
-20.86M
Short % of Float
19.04%
Insider Ownership
17.15%
Institutional Own.
78.90%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TSHA-102 Details Rett syndrome | Phase 1/2 Data readout | |
TSHA-102 Details Rett syndrome | Phase 1/2 Data readout | |
TSHA-118 Details Batten Disease | Failed Discontinued | |
TSHA-120 Details Giant Axonal Neuropathy | Failed Discontinued | |
TSHA-101 Details GM2 gangliosidosis | Failed Discontinued |